

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 June 2001 (14.06.2001)

PCT

(10) International Publication Number
WO 01/41679 A1


- (51) International Patent Classification⁷: **A61F 2/24**
- (21) International Application Number: **PCT/GB00/04673**
- (22) International Filing Date: 7 December 2000 (07.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
9928905.0 8 December 1999 (08.12.1999) GB
- (71) Applicant (for all designated States except US):
AORTECH EUROPE LIMITED [GB/GB]; Phoenix Crescent, Strathclyde Business Park, Bellshill, ML4 3NJ (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **O'CONNOR, Bernard** [GB/GB]; 18 Edgemont Street, Glasgow G41 3EN (GB). **WHEATLEY, David, John** [GB/GB]; 13 Lochend Drive, Glasgow, G61 1ED (GB). **BERNACCA, Gillian, Maureen** [GB/GB]; 4 Melrose Gardens, Glasgow G20 6RA (GB). **HAWORTH, William, Stafford** [GB/GB]; Glebe House, Lamington, Biggar ML12 6HW (GB).
- (74) Agent: **MURGITROYD & COMPANY**; 373 Scotland Street, Glasgow G5 8QA (GB).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **HEARTH VALVE PROSTHESIS AND METHOD OF MANUFACTURE**



(57) Abstract: The present invention provides a cardiac valve prosthesis comprising a frame and two or more leaflets (preferably three) attached to the frame. The leaflets are attached to the frame between posts, with a free edge which can seal the leaflets together when the valve is closed under back pressure. The leaflets are created in a mathematically defined shape allowing good wash-out of the whole leaflet orifice, including the area close to the frame posts, thereby relieving the problem of thrombus deposition under clinical implant conditions.

WO 01/41679 A1

1 **HEART VALVE PROSTHESIS AND METHOD OF MANUFACTURE**

2

3 FIELD OF THE INVENTION

4

5 The present invention relates to medical
6 implants, particularly cardiac and vascular implants
7 and prostheses. More specifically, the invention
8 relates to a cardiac valve prosthesis comprising a
9 frame and leaflets. Such valves may also be made
10 without rigid frames and may also be used as valves
11 in artificial hearts, whether the latter are intended
12 for permanent implantation or for temporary support
13 of a patient.

14

15 BACKGROUND OF THE INVENTION

16

17 In mammals the heart is the organ responsible
18 for maintaining an adequate supply of blood, and
19 hence of oxygen and nutrients, to all parts of the
20 body. Reverse flow of blood through the heart is

1 prevented by four valves which serve as the inlet and
2 outlet of each of the two ventricles, the pumping
3 chambers of the heart.

4 Dysfunction of one or more of these valves can
5 have serious medical consequences. Such dysfunction
6 may result from congenital defects, or from disease
7 induced damage. Forms of dysfunction include stenosis
8 (reduction in the orifice of the open valve) and
9 regurgitation (reverse flow through the closing or
10 closed valve), either of which increases the work
11 required by the heart to maintain the appropriate
12 blood flows to the body.

13 In many cases the only effective solution is to
14 replace the malfunctioning valve. A valve replacement
15 operation is expensive and requires specialised
16 facilities for open heart surgery. Replacement of
17 failed artificial heart valves carries increased risk
18 over the initial replacement, so there are practical
19 limits on the number of times reoperation can be
20 undertaken. Consequently, the design and materials of
21 an artificial valve must provide for durability of
22 the valve in the patient. The artificial valve must
23 also operate without high pressure gradients or undue
24 reverse flow during closing or when closed, because
25 these are the very reasons for which a replacement of
26 the natural valve is undertaken.

27 Mechanical valves, which use a ball or a disc or
28 a pair of pivoting rigid leaflets as the opening
29 member(s) can meet these combined requirements of
30 haemodynamic performance and durability.
31 Unfortunately, a patient who has had a mechanical

1 valve implanted must be treated with anticoagulants,
2 otherwise blood will clot on the valve. Clotting on
3 the valve can either restrict the movement of the
4 valve opening member(s), impairing valve function, or
5 can break free from the valve and obstruct blood
6 vessels downstream from the valve, or both. A patient
7 receiving a mechanical valve will be treated with
8 anticoagulants for life.

9 Valves excised from pigs and treated with
10 glutaraldehyde to crosslink and stabilise the tissue
11 are also used for replacement of defective valves.
12 These may be mounted on a more or less rigid frame,
13 to facilitate implantation, or they may be unmounted
14 and sewn by the surgeon directly to the vessel walls
15 at operation. A further type of valve replacement is
16 constructed from natural tissue, such as pericardium,
17 treated with glutaraldehyde and mounted on a frame.
18 Valves from pigs or made from other animal or human
19 tissue are collectively known as tissue valves. A
20 major advantage of tissue valves over mechanical
21 valves is that they are much less likely to provoke
22 the blood to clot, and so patients receiving tissue
23 valves are not normally given anticoagulants other
24 than during the immediate post operative period.
25 Unfortunately, tissue valves deteriorate over time,
26 often as a result of calcification of the crosslinked
27 natural tissue. This deterioration presents a
28 problem, particularly in young patients. Thus,
29 although the recipient of a tissue valve is not
30 required to take anticoagulants, the durability of
31 tissue valves is less than that of mechanical valves.

1 In third world countries, where rheumatic fever
2 is still common, the problems of valve replacement in
3 young patients are considerable. Anticoagulants,
4 required for mechanical valves, are impractical and
5 accelerated calcification of tissue valves precludes
6 their use.

7 In the Western world, life expectancy continues
8 to increase, and this results in a corresponding rise
9 both in patients requiring cardiac valve replacement,
10 and in those patients needing replacement of
11 deteriorating artificial valves implanted in the
12 past. There is, therefore, a need for a replacement
13 heart valve with good haemodynamics, extended
14 durability and having sufficiently low risk of
15 inducing clotting so that anticoagulants are not
16 necessary.

17 The natural heart valves use thin flexible
18 tissue leaflets as the closing members. The leaflets
19 move readily out of the orifice as blood begins to
20 flow through the valve so that flow through the open
21 valve is unrestricted by the leaflets. Tissue valves
22 function similarly, providing a relatively
23 unrestricted orifice when the valve is open. For
24 mechanical valves, on the other hand, the closing
25 member rotates in the orifice, but is not removed
26 from the orifice when the valve opens. This provides
27 some restriction to flow, but, more importantly,
28 disturbs the blood flow patterns. This disturbance to
29 the flow is widely held to initiate, or at least to
30 contribute significantly to, the observed tendency of
31 mechanical valves to produce clotting.

1 A number of trileaflet polyurethane valve
2 designs have been described.

3 A valve design, comprising a leaflet geometry
4 which was elliptical in the radial direction and
5 hyperbolic in the circumferential direction in the
6 closed valve position, with leaflets dip-coated from
7 non-biostable polyurethane solutions onto injection-
8 moulded polyurethane frames has attained durabilities
9 in excess of 800 million cycles during *in vitro*
10 fatigue testing (Mackay TG, Wheatley DJ, Bernacca GM,
11 Hindle CS, Fisher AC. New polyurethane heart valve
12 prosthesis: design, manufacture and evaluation.
13 *Biomaterials* 1996; 17:1857-1863; Mackay TG, Bernacca
14 GM, Wheatley DJ, Fisher AC, Hindle CS. *In vitro*
15 function and durability assessment of a polyurethane
16 heart valve prosthesis. *Artificial Organs* 1996;
17 20:1017-1025; Bernacca GM, Mackay TG, Wheatley DJ. *In*
18 *vitro* function and durability of a polyurethane heart
19 valve: material considerations. *J Heart Valve Dis*
20 1996; 5:538-542; Bernacca GM, Mackay TG, Wilkinson R,
21 Wheatley DJ. Polyurethane heart valves: fatigue
22 failure, calcification and polyurethane structure. *J*
23 *Biomed Mater Res* 1997; 34:371-379; Bernacca GM,
24 Mackay TG, Gulbransen MJ, Donn AW, Wheatley DJ.
25 Polyurethane heart valve durability: effects of
26 leaflet thickness. *Int J Artif Organs* 1997; 20:327-
27 331.). However, this valve design became
28 unacceptably stenotic in small sizes. Thus, a
29 redesign was effected, changing the hyperbolic angle
30 from the free edge to the leaflet base, and replacing
31 the injection-moulded frame with a rigid, high

1 modulus polymer frame. This redesign permitted the
2 use of a thinner frame, thus increasing valve orifice
3 area. This valve design, with a non-biostable
4 polyurethane leaflet material, was implanted in a
5 growing sheep model. Valve performance was good over
6 the six month implant period, but the region close to
7 the frame posts on the inflow side of the valve, at
8 which full leaflet opening was not achieved, suffered
9 a local accumulation of thrombus (Bernacca GM, Raco
10 L, Mackay TG, Wheatley DJ. Durability and function of
11 a polyurethane heart valve after six months *in vivo*.
12 Presented at the XII World Congress of International
13 Society for Artificial Organs and XXVI Congress of
14 the European Society for Artificial Organs,
15 Edinburgh, August 1999. Wheatley DJ, Raco L,
16 Bernacca GM, Sim I, Belcher PR, Boyd JS.
17 Polyurethane: material for the next generation of
18 heart valve prostheses? Eur. J. Cardio-Thorac. Surg.
19 2000; 17; 440-448). This valve design used non-
20 biostable polyurethane, which had tolerable
21 mechanical durability, but which showed signs of
22 polymer degradation after six months *in vivo*.

23 International Patent Application WO 98/32400
24 entitled "Heart Valve Prosthesis" discloses a similar
25 design, i.e. closed leaflet geometry, comprising
26 essentially a trileaflet valve with leaflets moulded
27 in a geometry derived from a sphere towards the free
28 edge and a cone towards the base of the leaflets. The
29 spherical surface, defined by its radius, is intended
30 to provide a tight seal when the leaflets are under
31 back pressure, with ready opening provided by the

1 conical segment, defined by its half-angle, at the
2 base of the leaflets. Were the spherical portion
3 located at the leaflet base it is stated that this
4 would provide an advantage in terms of the stress
5 distribution when the valve is closed and under back
6 pressure.

7 U.S. Patent No. 5,376,113 entitled "Closing
8 Member Having Flexible Closing Elements, Especially a
9 Heart Valve" issued December 27, 1994 to Jansen et
10 al. discloses a method of producing flexible heart
11 valve leaflets using leaflets attached to a base ring
12 with posts extending from this upon which the
13 leaflets are mounted. The leaflets are formed with
14 the base ring in an expanded position, being
15 effectively of planar sheets of polymer, which become
16 flaccid on contraction of the ring. The resulting
17 valve is able to maintain both a stable open and a
18 stable closed position in the absence of any
19 pulsatile pressure, though in the neutral unloaded
20 position the valve leaflets contain bending stresses.
21 As a consequence of manufacturing the valve from
22 substantially planar sheets, the included angle
23 between the leaflets at the free edge where they
24 attach to the frame is 60° for a three leaflet valve.

25 U.S. Patent No. 5,500,016 entitled "Artificial
26 Heart Valve" discloses a valve having a leaflet shape
27 defined by the mathematical equation $z^2 + y^2 = 2RL$
28 $(x-g) - \alpha(x-g)^2$, where g is the offset of the leaflet
29 from the frame, RL is the radius of curvature of the
30 leaflet at $(g, 0, 0)$ and α is the shape parameter and
31 is >0 and <1 .

1 A valve design having a partially open
2 configuration when the valve is not subject to a
3 pressure gradient, but assuming a fully-open position
4 during forward flow is disclosed in International
5 Patent Application WO 97/41808 entitled "Method for
6 Producing Heart Valves". The valve may be a
7 polyurethane trileaflet valve and is contained within
8 a cylindrical outer sleeve.

9 U.S. Patent Nos. 4,222,126 and 4,265,694
10 disclose a trileaflet polyurethane valve with
11 integral polyurethane elastomeric leaflets having
12 their leading edges reinforced with an integral band
13 of polymer and the leaflets reinforced radially with
14 thicker lines of polyurethane.

15 The problem of chronic thrombus formation and
16 tissue overgrowth arising from the suture ring of
17 valves has been addressed by extension of the valve
18 body on either side of the suture ring as disclosed
19 in U.S. Patent No. 4,888,009 entitled "Prosthetic
20 Heart Valve".

21 Current polyurethane valve designs have a number
22 of potential drawbacks. Close coaptation of leaflets,
23 while ensuring good valve closure, limits the wash-
24 out of blood during haemodynamic function,
25 particularly in the regions close to the stent posts
26 at the commissures. This region of stagnation is
27 likely to encourage local thrombogenesis, with
28 further restriction of the valve orifice in the
29 longer term as well as increasing the risk of
30 material embolising into the circulation. Associated
31 with the thrombosis may be material degradation (in

1 non-biostable polyurethanes) and calcification
2 resulting in localised stiffening the leaflets,
3 stress concentrations and leaflet failure. As
4 previously discussed, animal implants of a trileaflet
5 polyurethane valve design have indicated that
6 thrombus does tend to collect in this region,
7 restricting the valve orifice and damaging the
8 structure of the valve.

9 Present valve designs are limited by the
10 availability of suitable polyurethanes which possess
11 good mechanical properties as well as sufficient
12 durability to anticipate clinical functionality of up
13 to twenty years or more. Many low modulus materials,
14 which provide good hydrodynamic function, fail during
15 fatigue testing at unacceptably low durations, due to
16 their greater susceptibility to the effects of
17 accumulated strain. Higher modulus polyurethanes may
18 be better able to withstand repeated stress without
19 accumulating significant damage, but are too stiff to
20 provide good hydrodynamic function in conventional
21 almost-closed geometry valve designs. Current design
22 strategies have not been directed towards enabling
23 the incorporation of potentially more durable, higher
24 modulus leaflet materials, nor the creation of a
25 valve design that is able to maintain good
26 hydrodynamic function with low modulus polyurethanes
27 manufactured as thick leaflets.

28 The nature of the valve leaflet attachment to
29 the frame is such that, in many valve designs, there
30 is a region of leaflet close to the frame, which is
31 restrained by the frame. This region may extend some

1 distance into the leaflet before it interfaces with
2 the free-moving part of the leaflet, or may be
3 directly at the interface between frame and leaflet.
4 There thus exists a stress concentration between the
5 area of leaflet that is relatively mobile, undergoing
6 transition between fully open and fully closed, and
7 the relatively stationary commissural region. The
8 magnitude of this flexural stress concentration is
9 maximised when the design parameters predicate high
10 bending strains in order for the leaflet to achieve
11 its fully open position.

12 U.S. Patent Nos. 4,222,126 and 4,265,694
13 disclose a valve which uses thickened leaflet areas
14 to strengthen vulnerable area of the leaflets.
15 However this approach is likely to increase the
16 flexure stress and be disadvantageous in terms of
17 leaflet hydrodynamic function.

18 The major difficulties which arise in designing
19 synthetic leaflet heart valves can be explained as
20 follows. The materials from which the natural
21 trileaflet heart valves (aortic and pulmonary) are
22 formed have deformation characteristics particularly
23 suited to the function of such a valve. Specifically,
24 they have a very low initial modulus, and so they are
25 very flexible in bending, which occurs at low strain.
26 This low modulus also allows the leaflet to deform
27 when the valve is closed and loaded in such a way
28 that the stresses generated at the attachment of the
29 leaflets, the commissures, are reduced. The leaflet
30 material then stiffens substantially, and this allows
31 the valve to sustain the closed loads without

1 prolapse. Synthetic materials with these mechanical
2 properties are not available.

3 Polyurethanes can be synthesised with good blood
4 handling and good durability. They are available with
5 a wide range of mechanical properties, although none
6 has as low a modulus as the natural heart valve
7 material. Although they show an increase in modulus
8 at higher strains, this does not occur until strains
9 much higher than those encountered in leaflet heart
10 valves.

11 Polyurethanes have been the materials of choice
12 for synthetic leaflet heart valves in the last decade
13 or more. More recently, polyurethanes have become
14 available which are resistant to degradation when
15 implanted. They are clearly more suitable for making
16 synthetic leaflet heart valves than non-stable
17 polyurethanes, but their use suffers from the same
18 limitations resulting from their mechanical
19 properties. Therefore, design changes must be sought
20 which enable synthetic trileaflet heart valves to
21 function with the best available materials.

22 Key performance parameters which must be
23 considered when designing a synthetic leaflet heart
24 valve include pressure gradient, regurgitation, blood
25 handling, and durability.

26 To minimise the gradient across the open valve,
27 the leaflets must open wide to the maximum orifice
28 possible, which is defined by the inside diameter of
29 the stent. This means that there must be adequate
30 material in the leaflets so they can be flexed into a
31 tube of diameter equal to the stent internal

1 diameter. In addition, there has to be a low energy
2 path for this bending because the pressure forces
3 available to open the valve are small, and the lower
4 the gradient, the smaller the pressure becomes. All
5 the leaflets must open for the lowest cardiac output
6 likely to be encountered by that valve in clinical
7 service.

8 To minimise closing regurgitation (reverse flow
9 lost through the closing valve) the valve leaflets
10 must be produced at or close to the closed position
11 of the valve. To minimise closed valve regurgitation
12 (reverse flow through the valve once it has closed),
13 the apposition of the leaflets in the commissural
14 region is found to be key, and from this perspective
15 the commissures should be formed in the closed
16 position.

17 Proper blood handling means minimising the
18 activation both of the coagulation system and of
19 platelets. The material of construction of the valve
20 is clearly a very important factor, but flow through
21 the valve must also avoid exposing blood either to
22 regions of high shear (velocity gradient) or to
23 regions of relative stasis. Avoiding regions of high
24 shear is achieved if the valve opens fully, and
25 relative stasis is avoided if the leaflet/frame
26 attachment and the commissural region in particular
27 opens wide. This is not achieved with typical
28 synthetic materials when the commissures are molded
29 almost closed, because the stiffness of synthetics is
30 too high.

1 Durability depends to a large extent on the
2 material of construction of the valve leaflets, but
3 for any given material, lifetime will be maximised if
4 regions of high stress are avoided. The loads on the
5 closed valve are significantly greater than loads
6 generated during valve opening. Therefore, the focus
7 should be on the closed position. Stresses are
8 highest in the region of the commissures where loads
9 are transmitted to the stent, but they are reduced
10 when the belly of the leaflet is as low as
11 practicable in the closed valve. This means that
12 there must be sufficient material in the leaflet to
13 allow the desired low closing.

14

15 SUMMARY OF THE INVENTION

16

17 The present invention provides a cardiac valve
18 prosthesis comprising a frame and two or more
19 leaflets (preferably three) attached to the frame.
20 The leaflets are attached to the frame between posts,
21 with a free edge which can seal the leaflets together
22 when the valve is closed under back pressure. The
23 leaflets are created in a mathematically defined
24 shape allowing good wash-out of the whole leaflet
25 orifice, including the area close to the frame posts,
26 thereby relieving the problem of thrombus deposition
27 under clinical implant conditions.

28 The leaflet shape has a second design feature,
29 by which the pressure required to open the valve and
30 the pressure gradient across the valve in the open
31 position is reduced by creating a valve which is

1 partially open in its stable unstressed position.
2 Moulding the leaflets in a partially open position
3 permits them to open easily to a wider angle
4 resulting in an increased effective orifice area, for
5 any given polyurethane/elastomeric material. This
6 permits the use of materials from a wider range of
7 mechanical properties to fabricate the leaflets,
8 including those of a relatively stiff nature, and
9 also permits lower modulus materials to be
10 incorporated as thicker and hence more durable
11 leaflets, while retaining acceptable leaflet
12 hydrodynamic function.

13 A third design feature is the reduction of a
14 stress concentration in the vicinity of the
15 commissural region of the leaflets. In many valve
16 designs, there exists a region of localised high
17 bending where the opening part of the flexible
18 leaflet merges into the stationary region of the
19 leaflet adjacent to the valve frame. The current
20 design reduces the bending, and hence the local
21 stress concentration, in this region. This feature is
22 designed to enhance the valve durability.

23 The wide opening of the leaflet coaptation close
24 to the stent posts improves blood washout, reduces
25 thrombogenesis and minimises embolic risks to the
26 recipient, by allowing a clear channel for blood flow
27 throughout the whole valve orifice.

28 The partially open design acts to reduce the
29 fluid pressure required to open the valve. This in
30 turn results in lower pressure gradients across the
31 valve, allowing the use of durable, stiffer

1 polyurethanes to fabricate the valve which may be
2 better equipped to deal with a cyclic stress
3 application or thicker leaflets of lower modulus
4 polyurethanes, hence achieving good durability with
5 good hydrodynamic function. The position of the
6 leaflet in its stable unstressed state acts to reduce
7 the stress concentration resulting from leaflet
8 bending, hence increasing valve durability.

9 In one aspect the invention is a cardiac valve
10 prosthesis comprising a frame defining a blood flow
11 axis and at least two leaflets attached to the frame.
12 The at least two leaflets are configured to be
13 movable from an open to a closed position. The
14 leaflets have a blood inlet side and a blood outlet
15 side and are in the closed position when fluid
16 pressure is applied to the outlet side, and in the
17 open position when fluid pressure is applied to the
18 inlet side. The leaflets are in a neutral position
19 intermediate the open and closed position in the
20 absence of fluid pressure being applied to the
21 leaflets. The at least two leaflets include a first
22 leaflet. The first leaflet has a surface contour
23 such that an intersection of the first leaflet with
24 at least one plane perpendicular to the blood flow
25 axis forms a first composite wave. The first
26 composite wave is substantially defined by a first
27 wave combined with at least a second wave
28 superimposed over the first wave. The first wave has
29 a first frequency and the second wave has a second
30 frequency, different from the first frequency.
31 Alternatively, the first composite wave may be

1 defined by a first wave combined with second and
2 third waves superimposed over the first wave. The
3 third wave has a third frequency which is different
4 from the first frequency.

5 Both the first wave and the second wave may be
6 symmetric or asymmetric about a plane parallel to and
7 intersecting the blood flow axis and bisecting the
8 first leaflet. The first composite wave may be
9 symmetric or asymmetric about a plane parallel to and
10 intersecting the blood flow axis and bisecting the
11 first leaflet. The at least two leaflets may include
12 second and third leaflets. An intersection of the
13 second and third leaflets with a plane perpendicular
14 to the blood flow axis forms second and third
15 composite waves. The second and third composite
16 waves are substantially the same as the first
17 composite wave. The first and second waves may be
18 defined by an equation which is trigonometric,
19 elliptical, hyperbolic, parabolic, circular, a smooth
20 analytic function or a table of values. The at least
21 two leaflets may be configured such that they are
22 substantially free of bending stresses when in the
23 neutral position. The frame may be substantially
24 cylindrical having first and second ends, one of the
25 ends defining at least two scalloped edge portions
26 separated by at least two posts, each post having a
27 tip, and wherein each leaflet has a fixed edge joined
28 to a respective scalloped edge portion of the frame
29 and a free edge extending substantially between the
30 tips of two posts. The first and second waves may be
31 symmetric about a plane parallel to and intersecting

1 the blood flow axis and bisecting the first leaflet
2 or at least one of the first and second waves may be
3 symmetric about such plane. The first leaflet may
4 have a surface contour such that when the first
5 leaflet is in the neutral position an intersection of
6 the first leaflet with a plane parallel to and
7 intersecting the blood flow axis and bisecting the
8 first leaflet forms a fourth wave.

9 In another aspect the invention is a method of
10 making a cardiac valve prosthesis. The valve
11 prosthesis includes a frame defining a blood flow
12 axis substantially parallel to the flow of blood
13 through the valve prosthesis and at least two
14 flexible leaflets attached to the frame. The method
15 includes providing a forming element having at least
16 two leaflet forming surfaces. The forming element is
17 engaged with the frame. A coating is applied over
18 the frame and engaged forming element. The coating
19 binds to the frame. The coating over the leaflet
20 forming surfaces forms the at least two leaflets.
21 The at least two leaflets are configured to be
22 movable from an open to a closed position. The
23 leaflets have a blood inlet side and a blood outlet
24 side and are in the closed position when fluid
25 pressure is applied to the outlet side, and in the
26 open position when fluid pressure is applied to the
27 inlet side. The leaflets are in a neutral position
28 intermediate the open and closed position in the
29 absence of fluid pressure being applied to the
30 leaflets. The at least two leaflets include a first
31 leaflet. The first leaflet has a surface contour

1 such that the intersection of the first leaflet with
2 at least one plane perpendicular to the blood flow
3 axis forms a first composite wave. The first
4 composite wave is substantially defined by a first
5 wave combined with a second superimposed wave. The
6 first wave has a first frequency and the second wave
7 has a second frequency different from the first
8 frequency. After the coating is applied the forming
9 element is disengaged from the frame. The first
10 composite wave formed in the coating step may be
11 defined by a first wave combined with second and
12 third waves superimposed over the first wave. The
13 third wave has a third frequency which is different
14 from the first frequency.

15 The first and second waves formed in the coating
16 step may be either symmetric or asymmetric about a
17 plane parallel to and intersecting the blood flow
18 axis and bisecting the first leaflet. The first
19 composite wave formed in the coating step may be
20 symmetric or asymmetric about a plane parallel to and
21 intersecting the blood flow axis and bisecting the
22 first leaflet. The at least two leaflets formed in
23 the coating step may include second and third
24 leaflets. An intersection of the second and third
25 leaflets with a plane perpendicular to the blood flow
26 axis forms second and third composite waves,
27 respectively. The second and third composite waves
28 are substantially the same as the first composite
29 wave. The first and second waves formed in the
30 coating step may be defined by an equation which is
31 trigonometric, elliptical, hyperbolic, parabolic,

1 circular, a smooth analytic function or a table of
2 values.

3 The first and second waves in the coating step
4 may be symmetric about a plane parallel to and
5 intersecting the blood flow axis and bisecting the
6 first leaflet or at least one of the first and second
7 waves may be asymmetric about such plane. The at
8 least two leaflets in the coating step are configured
9 such that they are substantially free of bending
10 stresses when in the neutral position.

11 In a further aspect the invention is a cardiac
12 valve prosthesis comprising a frame defining a blood
13 flow axis and at least two leaflets attached to the
14 frame including a first leaflet. The first leaflet
15 has an internal surface facing the blood flow axis
16 and an external surface facing away from the blood
17 flow axis. The first leaflet is configured such that
18 a mean thickness of a first half of the first leaflet
19 is different than a mean thickness of a second half
20 of the first leaflet. The first and second halves
21 are defined by a plane parallel to and intersecting
22 the blood flow axis and bisecting the first leaflet.
23 The first leaflet may be further configured such that
24 a thickness of the first leaflet between the internal
25 and external surfaces along a cross section defined
26 by the intersection of a plane perpendicular to the
27 blood flow axis and the first leaflet changes
28 gradually and substantially continuously from a first
29 end of the cross section to a second end of the cross
30 section.

1 In another aspect the invention is a method of
2 making a cardiac valve prosthesis which includes a
3 frame defining a blood flow axis substantially
4 parallel to the flow of blood through the valve
5 prosthesis and at least two flexible leaflets
6 attached to the frame. The method includes providing
7 a mould having a cavity sized to accommodate the
8 frame, inserting the frame into the mould, inserting
9 the mould into an injection moulding machine, and
10 injecting molten polymer into the cavity of the mould
11 to form the at least two leaflets. The injection of
12 the molten polymer causes the at least two leaflets
13 to bond to the frame. The cavity is shaped to form
14 the at least two leaflets in a desired configuration.
15 The at least two leaflets are configured to be
16 movable from an open to a closed position. The
17 leaflets have a blood inlet side and a blood outlet
18 side and are in the closed position when fluid
19 pressure is applied to the outlet side, and in the
20 open position when fluid pressure is applied to the
21 inlet side. The leaflets are in a neutral position
22 intermediate the open and closed position in the
23 absence of fluid pressure being applied to the
24 leaflets. The at least two leaflets include a first
25 leaflet having a surface contour such that when the
26 first leaflet is in the neutral position an
27 intersection of the first leaflet with at least one
28 plane perpendicular to the blood flow axis forms a
29 first composite wave. The first composite wave is
30 substantially defined by a first wave combined with
31 at least a second superimposed wave. The first wave

1 may have a first frequency, the second wave may have
2 a second frequency, the first frequency being
3 different from the second frequency.

4 In a still further aspect the invention is a
5 method of designing a cardiac valve prosthesis which
6 includes a frame and at least two flexible leaflets
7 attached to the frame. The method includes defining
8 a first desired shape of the leaflets in a first
9 position, defining a second desired shape of the
10 leaflets in a second position different from the
11 first position, and conducting a draping analysis to
12 identify values of adjustable parameters defining at
13 least one of the first and second shapes. The
14 draping analysis ensures that the leaflets are
15 comprised of a sufficient amount and distribution of
16 material for the leaflets to assume both the first
17 and second desired shapes. Either of the first and
18 second positions in the defining steps may be a
19 closed position and the other of the first and second
20 positions may be a partially open position.

21

22 DESCRIPTION OF DRAWINGS

23

24 FIG. 1 is a diagrammatic view comparing the
25 shape of symmetric (solid line) and asymmetric
26 (dashed line) leaflets.

27 FIG. 2 is a perspective view of the valve
28 prosthesis in the neutral or partially open position.

29 FIG. 3 is a sectional view similar to the
30 sectional view along line 3-3 of Fig. 2 except that
31 Fig. 3 illustrates that view when the leaflets are in

1 the closed position and illustrates the function
2 which is used to define the shape of the closed
3 leaflet belly $X_{Closed}(Z)$.

4 FIG. 4A is a front view of the valve leaflet
5 shown in Fig. 2. Fig. 4B is in the same view as Fig.
6 4A and is a partial schematic view of the same closed
7 valve leaflet shown in Fig. 3 and illustrates that
8 $S(X, Y)_n$ and $S(X, Y)_{n-1}$ are contours enclosing the
9 leaflet between the function $X_{Closed}(Z)$ and the scallop
10 geometry.

11 FIG. 5 is a plot of an underlying function used
12 in defining the valve leaflet in the moulded leaflet
13 partially open position **P**.

14 FIG. 6 is a plot of a symmetrical superimposed
15 function used in defining the shape of the valve
16 leaflet in the moulded leaflet position **P**.

17 FIG. 7 is a plot of the composite function used
18 in construction of the moulded leaflet position **P**
19 resulting from combining an underlying function (Fig.
20 5) and a symmetric superimposed function (Fig. 6).

21 FIG. 8 is a plot of an asymmetric superimposed
22 function used in the construction of the moulded
23 leaflet position **P**.

24 FIG. 9 is a plot of the composite function
25 resulting from combining an underlying function
26 (Fig. 5) and an asymmetric function (Fig. 8).

27 FIG. 10 is a sectional view of the valve
28 leaflets in the neutral position along line 3-3 in
29 Fig. 2 and illustrates the function which is used to
30 define the shape of the moulded leaflet belly
31 $X_{Open}(Z)$.

1 FIG. 11A is a front view of the valve. Fig. 11B
2 is a partial schematic view of the valve leaflets of
3 Fig. 11A and illustrates that $P(X, Y)_n$ and $P(X, Y)_{n-1}$
4 are contours enclosing the leaflet between the
5 function $X_{open}(Z)$ and the scallop geometry.

6 FIG. 12 is a perspective view of a valve of the
7 present invention having symmetric leaflets.

8 FIG. 13 is a perspective view of a valve of the
9 present invention having asymmetric leaflets.

10 FIG. 14 is a side view of a former used in the
11 manufacture of the valve of the present invention.

12

13 DESCRIPTION OF THE INVENTION

14

15 a. Design Considerations

16 Consideration of the factors discussed above
17 results in the identification of certain design goals
18 which are achieved by the prosthetic heart valve of
19 the present invention. First, the prosthetic heart
20 valve must have enough material in the leaflet for
21 wide opening and low closing, but more than this
22 amount increases the energy barrier to opening. To
23 ensure that there is sufficient, but not an excess of
24 material, a draping analysis discussed in more detail
25 below is used. Second, to ensure sufficient material
26 for wide opening and low closing, the valve can only
27 be manufactured in a partially open position: (a) by
28 deforming the stent posts outwards during
29 manufacture; (b) by introducing multiple curves in
30 the leaflet free edge (but see below); (c) by making
31 the closed position asymmetric; and (d) combinations

1 of the above. Third, if there is enough material for
2 low closing and wide opening, the energy barrier to
3 opening may be high enough to prevent opening of all
4 leaflets at low flow. The energy barrier can be
5 minimised by: (a) introducing multiple curves in the
6 leaflet; (b) making the leaflet asymmetric; and
7 combinations of the above. Fourth, open commissures
8 are needed for blood handling and closed commissures
9 are needed for regurgitation, so the valve should
10 have partially open commissures. In particular the
11 included angle between adjacent leaflet free edges at
12 the valve commissures (for example see angle α of the
13 symmetric leaflets shown in Fig. 1) should be in the
14 range of 10-55°, preferably in the range 25-55° and
15 more preferably in the range of 40-55°.

16 As discussed above, the use of multiple curves
17 in the leaflet helps assure wide opening and more
18 complete closure of the valve and to minimise the
19 energy barrier to opening of the valve. However, the
20 introduction of multiple curves of more than 1.5
21 wavelengths to the leaflet can be a disadvantage.
22 While there may be sufficient material in the leaflet
23 to allow full opening, in order for this to happen,
24 the bends in the leaflet must straighten out
25 completely. The energy available to do this arises
26 only from the pressure gradient across the open
27 valve, which decreases as the leaflets becomes more
28 open, i.e. as the valve orifice area increases. This
29 energy is relatively small (the more successful the
30 valve design the smaller it becomes), and does not
31 provide enough energy to remove leaflet curves of

1 more than 1.5 wavelengths given the stiffness of the
2 materials available for valve manufacture. The result
3 is they do not straighten out and the valve does not
4 open fully.

5 A draping analysis is used as a first
6 approximation to full finite element analysis to
7 determine if the starting shape of a membrane is such
8 that it will take on a desired final shape when
9 placed in its final position. From a durability
10 standpoint the focus is on the closed position, and
11 the desired shape of the leaflet in its closed
12 position is defined. Draping analysis allows the
13 leaflet to be reformed in a partially open position.

14 Draping analysis assumes that very low energy
15 deformation is possible (in reality any form of
16 deformation requires energy). In order for this to
17 occur the bending stiffness of the leaflet/membrane
18 must be small, each element of the membrane should be
19 free to deform relative to its neighbour, and each
20 element should be free to change shape, i.e. the
21 shear modulus of the material is assumed to be very
22 low. In applying the draping analysis, it is assumed
23 that the leaflet can be moved readily from an
24 original defined closed position to a new position in
25 which it is manufactured. When the valve is actually
26 cycled, it is assumed that the leaflet when closing
27 will move from the manufactured position to the
28 originally defined closed position. This allows the
29 closed position to be optimized from a stress
30 distribution aspect, and the manufactured position to

1 be optimized from the point of view of reducing the
2 energy barrier to opening.

3 Both symmetric and asymmetric shapes of the
4 leaflet can allow incorporation of sufficient
5 material in the leaflet free edge to allow full
6 opening. FIG. 1 is a diagrammatic view comparing the
7 shape of symmetric (solid line) and asymmetric
8 (dashed line) leaflets and also showing the
9 commissure area 12 where the leaflets connect to the
10 frame. An advantage of the asymmetric shape is that
11 a region of higher radius of curvature 14 is produced
12 than is achieved with a symmetric curve having a
13 lower radius of curvature 16. This region can buckle
14 more readily and thereby the energy barrier to
15 opening is reduced.

16 An asymmetric leaflet also reduces the energy
17 barrier through producing unstable buckling in the
18 leaflet. During opening symmetric leaflets buckle
19 symmetrically i.e. the leaflet buckles are generally
20 mirrored about the centerline of the leaflet thus
21 balancing the bending energies about this centerline.
22 In the asymmetric valve the region of higher radius
23 buckles readily, and because these bending energies
24 are not balanced about the center line, this buckle
25 proceeds to roll through the leaflet producing a
26 sail-like motion producing a low energy path to open.

27 An additional feature of the asymmetric valve is
28 that the open position is also slightly asymmetric,
29 as a result of which it offers a somewhat helical
30 flow path, and this can be matched to the natural
31 helical sense of the aorta. Suggested benefits of

1 this helical flow path include reduction of shear
2 stress non-uniformity at the wall, and consequent
3 reduction of platelet activation.

4

5 b. The Valve Prosthesis

6 The valve prosthesis will be described with
7 reference to the accompanying drawings. Fig. 2 is a
8 perspective view of one embodiment of the heart valve
9 prosthesis of the present invention. The valve 10
10 comprises a stent or frame 1 and attached leaflets
11 2a, 2b, and 2c. The leaflets are joined to the frame
12 at scallops 5a, 5b, and 5c. Between each scallop is
13 post 8, the most down-stream part of which is known
14 as a stent tip 6. Leaflets 2a, 2b, and 2c have free
15 edges 3a, 3b, and 3c, respectively. The areas
16 between the leaflets at the stent tips 6 form
17 commissures 4.

18 The following describes a particular way of
19 designing a valve of the present invention. Other
20 different design methodology could be utilized to
21 design a valve having the structural features of the
22 valve disclosed herein. Five computational steps are
23 involved in this particular method:

- 24 (1) Define the scallop geometry (the scallop, 5,
25 is the intersection of the leaflet, 2, with
26 the frame, 1);
27 (2) Geometrically define a valve leaflet in the
28 closed position C;
29 (3) Map and compute the distribution of area
30 across the leaflet in the closed position;

- 1 (4) Rebuild the leaflet in a partially open
- 2 position **P**; and
- 3 (5) Match the computed leaflet area distribution
- 4 in the partially open or moulded position **P**
- 5 to the defined leaflet in the closed position
- 6 **C**. This ensures that when an increasing
- 7 closing pressure is applied to the leaflets,
- 8 they eventually assume a shape which is
- 9 equivalent to that defined in closed position
- 10 **C**.

11 This approach allows the closed shape of the
 12 leaflets in position **C** to be optimised for durability
 13 while the leaflets shaped in the moulded partially
 14 open shape **P** can be optimised for haemodynamics. This
 15 allows the use of stiffer leaflet materials for
 16 valves which have good haemodynamics. An XYZ co-
 17 ordinate system is defined as shown in Fig. 2, with
 18 the Z axis in the flow direction of blood flowing
 19 through the valve.

20 The leaflets are mounted on the frame, the shape
 21 of which results from the intersection of the
 22 aforementioned leaflet shape and a 3-dimensional
 23 geometry that can be cylindrical, conical or
 24 spherical in nature. A scallop shape is defined
 25 through intersecting the surface enclosed by the
 26 following equations with a cylinder of radius **R**
 27 (where **R** is the internal radius of the valve):

$$X_{ell} = E_{s0} - E_{sj} \cdot \sqrt{1 - \left(\frac{Z}{E_{sN}} \right)^2}$$

$$H_{sJ} = E_{sO} - E_{sJ} \sqrt{1 - \left(\frac{Z}{E_{sN}} \right)^2} - H_{sO}$$

$$H_{sN}(Z) = H_{sJ} \cdot \tan(60) \cdot f(Z)$$

1 where $f(Z)$ is a function changing with Z .

$$X_{hyp} = H_{sO} + H_{sJ} \sqrt{1 - \left(\frac{Y}{H_{sN}} \right)^2}$$

2 The shape of the scallop can be varied using the
3 constants E_{sO} , E_{sJ} , H_{sO} , $f(Z)$. The definition of
4 parameters used in these and the other equations
5 herein are contained in Table 4.

6 The shape of the leaflet under back pressure
7 (i.e. in the closed position **C**) can be approximated
8 mathematically using elliptical or hyperbolic co-
9 ordinates, or a combination of the above in an XYZ
10 co-ordinate system where XY is the plane of the valve
11 perpendicular to the blood flow and Z is the
12 direction parallel to the blood flow. The parameters
13 are chosen to define approximately the shape of the
14 leaflet under back pressure so as to allow convenient
15 leaflet re-opening and minimise the effect of the
16 stress component which acts in the direction parallel
17 to the blood flow, whilst also producing an effective
18 seal under back pressure.

19 The closed leaflet geometry in closed position **C**
20 is chosen to minimise stress concentrations in the
21 leaflet particularly prone to occur at the valve
22 commissures. The specifications for this shape
23 include:

- 1 (1) inclusion of sufficient material to allow a
- 2 large open-leaflet orifice;
- 3 (2) arrangement of this material to minimise
- 4 redundancy (excess material in the free edge,
- 5 3) and twisting in the centre of the free
- 6 edge, 3; and
- 7 (3) arrangement of this material to ensure the
- 8 free edge, 3, is under low stress i.e.
- 9 compelling the frame and leaflet belly to
- 10 sustain the back-pressure.

11 Fig. 3 is a partial sectional view (using the
 12 section 3-3 shown in Fig. 2) showing only the
 13 intended position of the leaflet in the closed
 14 position. The shape of this intended position is
 15 represented by the function $X_{Closed}(Z)$. This function
 16 can be used to arrange the shape of the leaflet in
 17 the closed position **C** to meet the aforementioned
 18 specification. The curve is defined using the
 19 following equation and manipulated using the
 20 constants E_{cJ} , E_{cO} , Z_{cO} and the functions $E_{cN}(Z)$ and
 21 $X_T(Z)$.

$$X_{Closed}(Z) = - \left[E_{cJ} \left(1 - \left(\frac{Z - Z_{cO}}{E_{cN}(Z)} \right)^2 \right) \right]^{0.5} + E_{cO} - X_T(Z)$$

22 where E_{cN} is a function changing linearly with Z and
 23 $X_T(Z)$ is a function changing nonlinearly with Z .

24 Thus the scallop shape and the function $X_{Closed}(Z)$
 25 are used to form the prominent boundaries for the
 26 closed leaflet in the closed position **C**. The

1 remaining part of the leaflet is formed using
2 contours $S(X, Y)_n$ sweeping from the scallop to the
3 closed leaflet belly function $X_{closed}(Z)$, where n is an
4 infinite number of contours, two of which are shown
5 in Fig. 4B.

6 The length of the leaflet (or contours $S(X, Y)_n$)
7 in the circumferential direction (XY) is calculated
8 and repeated in the radial direction (Z) yielding a
9 function $L(Z)$ which is used later in the definition
10 of the geometry in the partially open position P . The
11 area contained between respective contours is also
12 computed yielding a function $K(Z)$ which is also used
13 in the definition of the geometry in position P . The
14 area contained between contours is approximated using
15 the process of triangulation as shown in Fig. 4B.
16 This entire process can be shortened by reducing the
17 number of contours used to represent the surface
18 ($100 < n < 200$).

19 The aforementioned processes essentially define
20 the leaflet shape and can be manipulated to optimise
21 for durability. In order to optimise for
22 haemodynamics, the same leaflet is moulded in a
23 position P which is intermediate in terms of valve
24 opening. This entails moulding large radius curves
25 into the leaflet which then serve to reduce the
26 energy required to buckle the leaflet from the closed
27 to the open position. The large radius curves can be
28 arranged in many different ways. Some of these are
29 outlined herein.

30 The leaflet may be moulded on a dipping former
31 as shown in Fig. 14. Preferably the former is tapered

1 with an included angle θ so that the end 29 has a
2 diameter which is greater than the end 22. (This
3 ensures apposition of the frame and former during
4 manufacture.). In this case, the scallop shape,
5 defined earlier, is redefined to lie on a tapered
6 geometry (as opposed to the cylindrical geometry used
7 in the definition of the closed leaflet shape). This
8 is achieved by moving each point on the scallop
9 radially, and in the same movement, rotation of each
10 point about an X-Y plane coincident with the bottom
11 of the scallop, until each point lies on the tapered
12 geometry.

13 The geometry of the leaflet shape can be defined
14 as a trigonometric arrangement (or other mathematical
15 function) preferably sinusoidal in nature in the XY
16 plane, comprising one or more waves, and having
17 anchoring points on the frame. Thus the valve
18 leaflets are defined by combining at least two
19 mathematical functions to produce composite waves,
20 and by using these waves to enclose the leaflet
21 surface with the aforementioned scallop.

22 One such possible manifestation is a composite
23 curve consisting of an underlying low frequency
24 sinusoidal wave upon which a second higher frequency
25 sinusoidal wave is superimposed. A third wave having
26 a frequency different from the first and second waves
27 could also be superimposed over the resulting
28 composite wave. This ensures a wider angle between
29 adjacent leaflets in the region of the commissures
30 when the valve is fully open thus ensuring good wash-
31 out of this region.

1 The composite curve, and the resulting leaflet,
 2 can be either symmetric or asymmetric about a plane
 3 parallel to the blood flow direction and bisecting a
 4 line drawn between two stent tips such as, for
 5 leaflet 2a, the section along line 3-3 of Fig. 2.
 6 The asymmetry can be effected either by combining a
 7 symmetric underlying curve with an asymmetric
 8 superimposed curve or *vice versa*.

9 The following describes the use of a symmetric
 10 underlying function with an asymmetric superimposed
 11 function, but the use of an asymmetric underlying
 12 function will be obvious to one skilled in the art.
 13 The underlying function is defined in the XY plane
 14 and connects the leaflet attachment points to the
 15 scallop at a given height from the base of the valve.
 16 This underlying function shown in Fig. 5, can be
 17 trigonometric, elliptical, hyperbolic, parabolic,
 18 circular, or other smooth analytic function or could
 19 be a table of values.

20 Using sine functions, one possible underlying
 21 wave is shown in Fig. 5 and is defined using the
 22 following equation.

$$X_u = X_{(u,0)} + A_u \cdot \sin \left[\left(\frac{0.5\pi}{Y_{(u,0)}} \right) (Y - Y_{(u,0)}) \right]$$

23 The superimposed wave is defined in the XY
 24 plane, and connects the attachment points of the
 25 leaflet to the scallop at a given height above the
 26 base of the valve. The superimposed wave is of higher
 27 frequency than the underlying wave, and can be

1 trigonometric, elliptic, hyperbolic, parabolic,
 2 circular, or other smooth analytic function, or a
 3 table of values.

4 Using sine functions, one possible symmetric
 5 leaflet design is formed when the underlying wave is
 6 combined with a superimposed wave formed using the
 7 following equation.

$$X_s = -A_s \cdot B_s(Y) \sin \left[\left(\frac{1.5\pi}{Y_{(n,0)}} \right) (Y - Y_{(n,0)}) \right]$$

8 A_s can be varied across the leaflet to produce
 9 varying wave amplitude across the leaflet, for
 10 example lower amplitude at the commissures than in
 11 the leaflet centre. B_s can be varied to adjust the
 12 length of the wave. The superimposed wave is shown
 13 in Fig. 6. The composite wave formed by combining
 14 the underlying wave (Fig. 5) with the superimposed
 15 wave (Fig. 6) is shown in Fig. 7.

16 Using sine functions, one possible asymmetric
 17 leaflet design is formed when the underlying wave
 18 (Fig. 5) is combined with a superimposed wave formed
 19 using the following equation.

$$X_s = -A_s \cdot B_s(Y) \sin \left[\left(\frac{\pi}{Y_{(n,0)}} \right) (Y - Y_{(n,0)}) \right]_0^{Y_{(n,0)}}$$

$$X_s = 0.5 \cdot A_s \cdot B_s(Y) \sin \left[\left(\frac{2.0\pi}{Y_{(n,0)}} \right) Y \right]_{(-Y_{(n,0)})}^0$$

1 A_s can be varied across the leaflet to produce
 2 varying wave amplitude across the leaflet, for
 3 example lower amplitude at the commissures than in
 4 the leaflet centre. $B_s(Y)$ can be varied to adjust the
 5 length of the wave. The superimposed wave is shown
 6 in Fig. 8. The resulting asymmetric composite wave
 7 is shown in Fig. 9. The composite wave $W(X_c, Y_c)_n$ is
 8 created by offsetting the superimposed wave normal to
 9 the surface of the underlying wave (Figs. 7, 9).

10 While the general shape of the leaflet in
 11 position P has been determined using the composite
 12 wave, at this stage it is not specified in any
 13 particular position. In order to specify the position
 14 of P , the shape of the partially open leaflet
 15 position can be defined as $X_{open}(Z)$. This is shown as
 16 reference numeral 7 in Fig. 10.

17 One possible function determining this shape is
 18 given as follows:

$$X_{open}(Z) = - \left[E_{oJ} \left(1 - \left(\frac{Z - Z_{oQ}}{E_{oN}} \right)^2 \right) \right]^{0.5} + E_{oO}$$

19 In order to manipulate the composite wave to
 20 produce the belly shape $X_{open}(Z)$ the respective
 21 amplitudes of the individual sine waves can be varied
 22 from the free edge to the leaflet base. For example,
 23 the degree of 'openness' of the leaflet in position P
 24 can be varied throughout the leaflet.

25 The composite wave is thus defined to produce
 26 the moulded "buckle" in the leaflet, and $X_{open}(Z)$ is
 27 used to define the geometry of the leaflet at

1 position **P**. At this stage it may bear no
2 relation to the closed leaflet shape in position **C**.
3 In order to match the area distribution of both
4 leaflet positions, (thus producing essentially the
5 same leaflet in different positions) the composite
6 wave length is iterated to match the length of the
7 relevant leaflet contour in position **C**. Thus the
8 amplitude and frequency of the individual waves can
9 be varied in such a manner as to balance between: (a)
10 producing a resultant wave the length of which is
11 equal to the relevant value in the length function
12 $L(Z)$ thus approximating the required closed shape
13 when back pressure is applied, and (b) allowing
14 efficient orifice washout and ready leaflet opening.
15 Also the area contained between the contours in the
16 open leaflet is measured using the same process of
17 triangulation as in the closed position **C**, and is
18 iterated until it matches with the area contained
19 between relevant contours in position **C** (denoted
20 $K(Z)$) (through tilting the contours in **P** relative to
21 each other). Thus the composite waves $(P(X,Y)_n)$
22 pertaining to the contour n and length $L(Z)$ can be
23 tilted at an angle to the XY plane about attachment
24 points $X_{(n,0)}$, $Y_{(n,0)}$ and $X_{(n,0)}$, $-Y_{(n,0)}$ until the correct
25 area is contained between $P(X,Y)_n$ and $P(X,Y)_{n-1}$ (See
26 Figs. 10 & 11).

27 This process identifies the values of B_s , A_u and
28 the contour tilt angle to be used in constructing the
29 mould for the valve leaflet. As long as the constants
30 such as B_s and A_u , and the tilt angle of the contours
31 relative to the XY plane, are known, the surface of

1 the leaflet in its moulded position can be
2 visualised, enclosed and machined in a conventional
3 manner. As a result of this fitting process the
4 composite wave retains the same basic form but
5 changes in detail from the top of the leaflet to the
6 bottom of the leaflet. A composite wave can be
7 defined in the leaflet surface as the intersection of
8 the leaflet surface with a plane normal to the Z
9 axis. This composite wave will have the same general
10 form as the composite wave used in the leaflet design
11 but will differ from it in detail as a result of the
12 tilting process described above.

13 In summary therefore one possible method of
14 designing the leaflet according to the present
15 invention is in the following way:

- 16 (1) Define a scallop shape;
- 17 (2) Define a shape approximating the shape of the
18 closed leaflet using elliptical, hyperbolic,
19 parabolic or circular functions, smooth
20 analytical functions or table of values;
- 21 (3) Compute the functions $L(Z)$ and $K(Z)$, which
22 define the length of the leaflet in the XY
23 plane along the Z axis and the area
24 distribution of the leaflet along the Z axis;
- 25 (4) Use one or more associated sine waves to
26 generate a geometry which is partially-open,
27 which pertains to a leaflet position which is
28 between the two extreme conditions of normal
29 valve function, i.e. leaflet open and leaflet
30 closed;

1 (5) Vary the frequency and amplitude of the
2 sinewaves to fit to the length function $L(Z)$
3 and the angle at which the contour is tilted
4 to the XY plane to fit to the area function
5 $K(Z)$; and

6 (6) The respective amplitudes of the individual
7 sine waves can be varied from the free edge
8 to leaflet base, for example the degree of
9 'openness' of the leaflet can be varied
10 throughout the leaflet.

11 Herein are some examples of how this invention
12 can be put into practice. Using the scallop constants
13 in Table 1, the constants required to produce an
14 example of a symmetric leaflet valve and an example
15 of an asymmetric leaflet valve are given in Table 2
16 and Table 3 respectively. These constants are used in
17 conjunction with the aforementioned equations to
18 define the leaflet geometry.

19 With one leaflet described using the
20 aforementioned equations, the remaining two leaflets
21 are generated by rotating the geometry about the Z
22 axis through 120° and then through 240° . These
23 leaflet shapes are inserted as the leaflet forming
24 surfaces of the dipping mould (otherwise known as a
25 dipping former), which then forms a 3-dimensional
26 dipping mould. The composite wave described in the
27 aforementioned equations, therefore substantially
28 defines the former surface which produces the inner
29 leaflet surface.

30 As seen in Fig. 14 the dipping mould 20 is
31 slightly tapered so that the end 29 has a diameter

1 which is greater than the end 22, and has a first end
2 22 having an outside diameter slightly smaller than
3 the inside diameter of the frame. The former
4 includes at least two and preferably three leaflet
5 forming surfaces 24 which are defined by scalloped
6 edges 26 and flats 28. Sharp edges in the
7 manufacturing former and on the frame are radiused to
8 help reduce stress concentrations in the finished
9 valve. During the dip moulding process the frame is
10 inserted over end 22 of the former so that the
11 scallops 5 and stent posts 8 of the frame align with
12 the scalloped edges 26 and flats 28 of the former.
13 The leaflet forming surfaces 24 are configured to
14 form leaflets during the moulding process which have
15 the geometry described herein. This mould can be
16 manufactured by various methods, such as, machining,
17 electrical discharge machining, injection moulding.
18 In order that blood flow is not disturbed, a high
19 surface finish on the dipping mould is essential.

20 For the frame there are preferably three posts
21 with leaflets hung on the frame between the posts. A
22 crown-like frame or stent, 1, is manufactured with a
23 scallop geometry, which matches the dipping mould
24 scallop. The frame scallop is offset radially by
25 0.1mm to allow for the entire frame to be coated with
26 a thin layer of leaflet material to aid adhesion of
27 the leaflets. Leaflets may be added to the frame by a
28 dip-moulding process, using a dipping former machined
29 or moulded to create the multiple sinewave form.

30 The material of preference should be a semi-
31 rigid fatigue- and creep-resistant frame material

1 such as PEEK, high modulus polyurethane, titanium,
2 reinforced polyurethane, or polyacetal (Delrin)
3 produced by machining or injection-moulding etc.
4 Alternatively, a relatively low modulus polymer may
5 be used, which may be fibre-reinforced, to more
6 closely mimic the aortic wall. The frame can be
7 machined or injection moulded, and is manufactured
8 preferably from polyetheretherketone (PEEK) or
9 polyacetal (Delrin).

10 The first stage of valve manufacture entails
11 dipping the frame in a polyurethane solution
12 (preferably Elast-EonTM manufactured by Elastomedic,
13 Sydney Australia) in order to apply a coating of
14 approximately 0.1mm thick. Having dried the frame
15 with applied coating in an oven overnight, it is
16 placed on the dipping former and aligned with the
17 former scallops. The combination of frame and three
18 dimensional dipping mould is then dipped into
19 polyurethane solution, which forms a coating of
20 solution on frame and mould. This coating flows
21 slowly over the entire mould surface ensuring a
22 smooth coating. The new coating on the frame and
23 dipping mould solvates the initial frame coating thus
24 ensuring a good bond between leaflet and frame. The
25 dipping mould with polyurethane covering is dried in
26 an oven until all the solvent has been removed. One
27 or more dips may be used to achieve a leaflet with a
28 mean thickness between 40µm and 500µm. The shape of
29 the former, and the viscosity and solvent interactive
30 properties of the polyurethane solution, control the
31 leaflet thickness and the distribution of thickness

1 over the leaflet. A dipping process does not allow
2 precise control of leaflet thickness and its
3 variation across a leaflet. In particular surfaces
4 that are convex on the dipping former result in
5 reduced leaflet thickness when compared with surfaces
6 that are concave. Additionally the region of the
7 leaflet adjacent to the frame essentially provides a
8 very small concave radius which traps further polymer
9 solution and this results in thickening of these
10 regions.

11 The shape of the former is substantially defined
12 by the composite wave. Radiusing and polishing of
13 the former can both contribute to some variation of
14 the shape. The shape of the inner surface of the
15 leaflets will closely replicate the shape of the
16 former. The shape of the outer surface of the
17 leaflets will be similar to the shape of the inner
18 surface but variations will result from the
19 processing properties of the polymer solution and
20 details of the dipping process used to produce the
21 valve. The leaflet may be formed from polyurethanes
22 having a Young's modulus less than 100MPa, preferably
23 in the range 5 to 50 MPa.

24 The valve is next removed from the dipping
25 mould. The stent posts, which had been deflected by
26 the taper on the former, now recover their original
27 position. The shape of the leaflets changes slightly
28 as a result of the movement of the stent posts.

29 At this stage the dipping mould and frame is
30 covered with an excess of polyurethane due to the
31 drain-off of the polymer onto the region of the mould

1 known as the drain-off area 30. Leaflet free edges
2 may be trimmed of excess material using a sharp blade
3 rotated around the opened leaflets or using laser-
4 cutting technology.

5 An alternate valve manufacturing method is
6 injection moulding. A mould is constructed with a
7 cavity which allows the valve frame to be inserted in
8 the mould. The cavity is also designed with the
9 leaflet geometry, as defined above, as the inner
10 leaflet surface. A desired thickness distribution is
11 defined for the leaflet and the outer leaflet surface
12 of the mould is constructed by adding the leaflet
13 thickness normally to the inner leaflet surface. The
14 leaflet may be of uniform thickness throughout, in
15 the range 40 to 500 microns, preferably 50 to 200
16 microns, more preferably 80 to 150 microns. The
17 leaflet may be thickened towards its attachment to
18 the frame. Alternatively the thickness of the
19 leaflet, along a cross-section defined by the
20 intersection of a plane perpendicular to the blood
21 flow axis and the leaflet, can change gradually and
22 substantially continuously from a first end of the
23 cross-section (i.e. first edge of the leaflet) to a
24 second end of the cross-section (i.e. second edge of
25 the leaflet) in such a way that the mean thickness of
26 the first half of the leaflet is different from the
27 mean thickness of the second half of the leaflet.
28 This mould is inserted in a conventional injection
29 moulding machine, the frame is inserted in the mould
30 and the machine injects molten polymer into the
31 cavity to form the leaflets and bond them to the

1 frame. The polymer solidifies on cooling and the
2 mould is opened to allow the complete valve to be
3 removed.

4 The leaflets may also be formed using a
5 reaction-moulding process (RIM) whereby the polymer
6 is synthesised during the leaflet forming. A mould is
7 constructed as described above. This mould is
8 inserted in a reaction-injection moulding machine,
9 the frame is inserted in the mould and the machine
10 injects a reactive mixture into the cavity. The
11 polymer is produced by the reaction in the cavity to
12 form the leaflets and bond them to the frame. When
13 the reaction is complete, the mould is opened to
14 allow the complete valve to be removed.

15 Yet a further option is to compression mould a
16 valve initially dipped. This approach allows the
17 leaflet thickness or thickness distribution to be
18 adjusted from that initially produced. By varying
19 the thickness of the leaflets the dynamics of the
20 valve opening and closing can be modified. For
21 example, the thickness of the leaflet along a cross-
22 section defined by the intersection of a plane
23 perpendicular to the blood flow axis and the leaflet
24 can be varied so that the thickness changes gradually
25 and substantially continuously from a first end of
26 the cross-section (i.e. first edge of the leaflet) to
27 a second end of the cross-section (i.e. second edge
28 of the leaflet) in such a way that the mean thickness
29 of the first half of the leaflet is different from
30 the mean thickness of the second half of the leaflet.
31 This will result in the thinner half of the leaflet

1 opening first and creating a sail-like opening motion
2 along the free edge of the leaflet.

3 Leaflet shape resulting from conventional
4 injection moulding, reaction injection moulding or
5 compression moulding, is substantially defined by the
6 composite wave described above. It will differ in
7 detail for many of the same reasons identified for
8 dip moulding.

9 The valves of the present invention are
10 manufactured in the neutral position or close to it
11 and are therefore substantially free of bending
12 stresses in this position. As a result when the
13 leaflet is moved to its closed position the total
14 bending energy at the leaflet center free edge and at
15 the commissures is reduced compared to a valve made
16 according to U.S. Patent No. 5,376,113.

17 The valves of the present invention may be used
18 in any required position within the heart to control
19 blood flow in one direction, or to control flow
20 within any type of cardiac assist device.

21 The following examples use the same scallop
22 geometry described using the constants set forth in
23 Table 1: While the examples described herein relate
24 to one valve size, the same method can be used to
25 produce valves from a wide range of sizes. This can
26 be carried out by modifying the constants used in the
27 equations, by rescaling the bounding curves such as
28 $X_{closed}(Z)$ and computing and iterating in the normal
29 fashion or by rescaling the leaflet.

30

31

	values (mm)
R	11.0
E_{SO}	21.7
E_{SJ}	21.5
E_{SN}	13.8
H_{SO}	0.18
$f(Z)$	$(0.05 \cdot Z) + 1.0$

Table 1

1 Example 1.

2 The parameters described in the preceding
3 sections are assigned the values set forth in Table 2
4 and are used to manufacture a symmetric valve. The
5 included angle between adjacent leaflet free edges at
6 the valve commissure for this valve is approximately
7 50°.

Parameter	Value (mm)
<i>Closed position</i>	
Z_{CO}	0
Z_{CO}	0.0
$E_{CN}(Z)$	$E_{CN}=3.0 \cdot Z+50.3$
E_{CO}	22.0
E_{CJ}	20.0
$X_T(Z)$	0.0
<i>Partially-open position</i>	
θ	12.7°
E_{OJ}	50.0

Z_{oo}	4.0
E_{oo}	51.8
E_{oN}	27.7
A_u	Result from iteration procedure finds that A_u varies from $1e-5$ at the leaflet base to 5.1 at 4mm from the leaflet base to 3.8 at the free edge.
A_s	Result from iteration procedure finds that A_s varies from $1e-3$ at the leaflet base to 1.6 at 3mm from the leaflet base to 0.6 at the free edge.
$B_s(Y)$	1.0

Table 2

1 Fig. 12 shows the symmetric valve which is
2 manufactured, using the values outlined in Table 1
3 and Table 2.

4

5 Example 2

6 The parameters described in the preceding
7 sections are assigned the values set forth in Table 3
8 and are used to manufacture an asymmetric valve. The
9 included angle between adjacent leaflet free edges at
10 the valve commissure for this valve is approximately
11 48° .

Parameter	Value (mm)
<i>Closed position</i>	
Z_{CO}	0.0
$E_{CN}(Z)$	$E_{CN}=3.0.Z+48.9$
E_{CO}	18.4
E_{CJ}	20.0
$X_{T(Z)}$	$X_{T(n-1)}=0.97.(X_{T(n)})$ where $X_{T(free\ edge)}=2.1$
<i>Partially-open position</i>	
θ	7.1°
E_{OJ}	50.0
Z_{OO}	5.0
E_{OO}	51.5
E_{ON}	29.0
A_u	Result from iteration procedure finds that A_u varies from $1e-5$ at the leaflet base to 3.1 at 3mm from the leaflet base to 2.2 at 9mm from the leaflet base to 3.8 at the free edge.
A_s	Result from iteration procedure finds that A_s varies from $1e-3$ at the leaflet base to 1.1 at 6mm from the leaflet base to 0.4 at the free edge.
$B_s(Y)$	$B_s(Y)=(Y-c)/m$ where $B_s=1$ at leaflet base and $m=5.04$ and $c=-15.1$ at leaflet free edge.

Table 3

1 Fig. 13 shows the valve which is manufactured
2 using the values outlined in Table 1 and Table 3.
3

Definition of parameters	
R	Internal radius of valve
Scallop (Fig. 2)	
X_{ell} , H_{SJ} , H_{SN} , X_{hyp} are used to define a surface which, when intersected with a cylinder, scribe a function which forms the scallop for one leaflet. This method for creating a scallop is described in Mackay et al. Biomaterials 17 1996. although an added variable $f(Z)$ is used for added versatility.	
X_{ell}	Scribes an ellipse in the radial direction.
X_{hyp}	Scribes a hyperbola in the circumferential direction.
E_{SO}	Ellipse X-axis offset
E_{SJ}	Major axis of the ellipse
E_{SN}	Minor axis of the ellipse
H_{SJ}	Major axis of the hyperbola
H_{SN}	Minor axis of the hyperbola
H_{SO}	Hyperbola x-axis offset
$f(Z)$	Creates a varying relationship between H_{SN} and H_{SJ}
Closed Leaflet geometry C (Figs. 3 & 4)	
$X_{closed}(Z)$ is defined as an ellipse (with a minor axis $E_{CN}(Z)$ which changes with Z) in the XZ axis in the plane defined in Fig. 2 by cutting plane 3-3. It is defined using the following constants and functions.	

Z_{co}	Closed ellipse Z-axis offset
$E_{CN}(Z)$	Closed ellipse minor axis which changes with Z
E_{co}	Closed ellipse X-axis offset
E_{cJ}	Closed ellipse major axis
$X_T(z)$	Offset function which serves to increase the amount of material in the belly
Moulded position P	
<p>P is enclosed by a number (n) of contours $P(X,Y)_n$ which run from one side of the scallop to the other. The underlying function X_u is used in defining both symmetric and asymmetric leaflets. X_u is simply an ellipse (or other such function) running in a plane from one side of the scallop to the other. The points on the scallop are designated $X_{(n,0)}$, $Y_{(n,0)}$ where n refers to the contour number (see Figs. 5,7,9,11B).</p>	
Y	Variable in plane from $Y_{(n,0)}$ to $-Y_{(n,0)}$
A_u	A_u is the amplitude of the underlying wave
A_s	A_s is the amplitude of the superimposed wave
B_s(Y)	B_s is a function which biases the wave amplitude in a defined way, e.g. the amplitude of the wave can be increased near the commissure if so desired.
Composite Curve (Figs. 7 & 9)	
X_c	X coordinate for defining the composite curve. This is derived using X_u and X_s
Y_c	Y coordinate for defining the composite curve. This is derived using X_u and X_s

Open Leaflet position (Fig. 10)	
$X_{open}(Z)$ is defined as an ellipse in the XZ axis in the plane defined in Fig. 2 by cutting plane 3-3. The contours defined in Composite Curve are married to the Open Leaflet position $X_{open}(Z)$ to produce the moulded leaflet P . It is defined using the following constants.	
E_{oJ}	Open ellipse major axis
Z_{oo}	Open ellipse Z-axis offset
E_{oo}	Open ellipse X-axis offset
E_{oN}	Open ellipse minor axis
θ	Former taper angle

1
2

Table 4

1 What is claimed is:

2

3 1. A cardiac valve prosthesis comprising:

4 a frame defining a blood flow axis; and

5 at least two flexible leaflets attached to

6 the frame, the at least two leaflets being

7 configured to be movable from an open to a

8 closed position, the at least two leaflets

9 having a blood inlet side and a blood outlet

10 side, the at least two leaflets being in the

11 closed position when fluid pressure is applied

12 to the outlet side, being in the open position

13 when fluid pressure is applied to the inlet side

14 and being in a neutral position intermediate the

15 open and closed position in the absence of fluid

16 pressure being applied to the leaflets, the at

17 least two leaflets including a first leaflet

18 having a surface contour such that when the

19 first leaflet is in the neutral position an

20 intersection of the first leaflet with at least

21 one plane perpendicular to the blood flow axis

22 forms a first composite wave, the first

23 composite wave being substantially defined by a

24 first wave combined with at least a second wave

25 superimposed over the first wave, the first wave

26 having a first frequency, the second wave having

27 a second frequency, the first frequency being

28 different from the second frequency.

29

30 2. The valve prosthesis of claim 1 wherein the

31 first composite wave is defined by a first wave

1 combined with second and third waves superimposed
2 over the first wave, the third wave having a third
3 frequency which is different from the first
4 frequency.

5

6 3. The valve prosthesis of claim 1 wherein the
7 first wave is symmetric about a plane parallel to and
8 intersecting the blood flow axis and bisecting the
9 first leaflet.

10

11 4. The valve prosthesis of claim 1 wherein the
12 first wave is asymmetric about a plane parallel to
13 and intersecting the blood flow axis and bisecting
14 the first leaflet.

15

16 5. The valve prosthesis of claim 1 wherein the
17 second wave is symmetric about a plane parallel to
18 and intersecting the blood flow axis and bisecting
19 the first leaflet.

20

21 6. The valve prosthesis of claim 1 wherein the
22 second wave is asymmetric about a plane parallel to
23 and intersecting the blood flow axis and bisecting
24 the first leaflet.

25

26 7. The valve prosthesis of claim 3 wherein the
27 second wave is symmetric about a plane parallel to
28 and intersecting the blood flow axis and bisecting
29 the first leaflet.

30

1 8. The valve prosthesis of claim 3 wherein the
2 second wave is asymmetric about a plane parallel to
3 and intersecting the blood flow axis and bisecting
4 the first leaflet.

5

6 9. The valve prosthesis of claim 4 wherein the
7 second wave is symmetric about a plane parallel to
8 and intersecting the blood flow axis and bisecting
9 the first leaflet.

10

11 10. The valve prosthesis of claim 4 wherein the
12 second wave is asymmetric about a plane parallel to
13 and intersecting the blood flow axis and bisecting
14 the first leaflet.

15

16 11. The valve prosthesis of claim 1 wherein the
17 first composite wave is symmetric about a plane
18 parallel to and intersecting the blood flow axis and
19 bisecting the first leaflet.

20

21 12. The valve prosthesis of claim 1 wherein the
22 composite wave is asymmetric about a plane parallel
23 to and intersecting the blood flow axis and bisecting
24 the first leaflet.

25

26 13. The valve prosthesis of claim 1 wherein the at
27 least two leaflets further include second and third
28 leaflets and wherein an intersection of the second
29 and third leaflets with the plane perpendicular to
30 the blood flow axis forms second and third composite
31 waves, respectively, the second and third composite

1 waves being substantially the same as the first
2 composite wave.

3

4 14. The valve prosthesis of claim 1 wherein the
5 first wave is defined by an equation which is one of
6 trigonometric, elliptical, hyperbolic, parabolic,
7 circular, a smooth analytic function and a table of
8 values.

9

10 15. The valve prosthesis of claim 1 wherein the
11 second wave is defined by an equation which is one of
12 trigonometric, elliptical, hyperbolic, parabolic,
13 circular, a smooth analytic function and a table of
14 values.

15

16 16. The valve prosthesis of claim 1 wherein the at
17 least two leaflets are configured such that they are
18 substantially free of bending stresses when in the
19 neutral position.

20

21 17. The valve prosthesis of claim 1 wherein the
22 frame is substantially cylindrical having first and
23 second ends, one of the ends defining at least two
24 scalloped edge positions separated by at least two
25 posts, each post having a tip, and wherein each
26 leaflet has a fixed edge joined to a respective
27 scalloped edge portion of the frame and a free edge
28 extending substantially between the tips of the at
29 least two posts.

30

1 18. The valve prosthesis of claim 11 wherein the
2 first and second waves are symmetric about a plane
3 parallel to and intersecting the blood flow axis and
4 bisecting the first leaflet.

5

6 19. The valve prosthesis of claim 12 wherein at
7 least one of the first and second waves is asymmetric
8 about a plane parallel to and intersecting the blood
9 flow axis and bisecting the first leaflet.

10

11 20. The valve prosthesis of claim 1 wherein the
12 first leaflet has a surface contour such that when
13 the first leaflet is in the neutral position an
14 intersection of the first leaflet with a plane
15 parallel to and intersecting the blood flow axis and
16 bisecting the first leaflet forms a fourth wave.

17

18 21. A method of making a cardiac valve prosthesis
19 which includes a frame defining a blood flow axis
20 substantially parallel to the flow of blood through
21 the valve prosthesis and at least two flexible
22 leaflets attached to the frame, the method
23 comprising:

24 providing a forming element having at least
25 two leaflet forming surfaces;

26 engaging the forming element to the frame;

27 applying a coating over the frame and

28 engaged forming element, the coating binding to

29 the frame, the coating over the leaflet forming

30 surfaces forming the at least two flexible

31 leaflets, the at least two leaflets being

56.

1 configured to be movable from an open to a
2 closed position, the at least two leaflets
3 having a blood inlet side and a blood outlet
4 side, the at least two leaflets being in the
5 closed position when fluid pressure is applied
6 to the outlet side, being in the open position
7 when fluid pressure is applied to the inlet side
8 and being in a neutral position intermediate the
9 open and closed position in the absence of fluid
10 pressure being applied to the leaflets, the at
11 least two leaflets including a first leaflet
12 having a surface contour such that when the
13 first leaflet is in the neutral position an
14 intersection of the first leaflet with at least
15 one plane perpendicular to the blood flow axis
16 forms a first composite wave, the first
17 composite wave being substantially defined by a
18 first wave combined with at least a second
19 superimposed wave, the first wave having a first
20 frequency, the second wave having a second
21 frequency, the first frequency being different
22 from the second frequency; and
23 disengaging the forming element from the
24 frame.

25
26 22. The method of claim 21 wherein the first
27 composite wave formed in the coating step is defined
28 by a first wave combined with second and third waves
29 superimposed over the first wave, the third wave
30 having a third frequency which is different from the
31 first frequency.

1

2 23. The method of claim 21 wherein the first wave
3 formed in the coating step is symmetric about a plane
4 parallel to and intersecting the blood flow axis and
5 bisecting the first leaflet.

6

7 24. The method of claim 21 wherein the first wave
8 formed in the coating step is asymmetric about a
9 plane parallel to and intersecting the blood flow
10 axis and bisecting the first leaflet.

11

12 25. The method of claim 21 wherein the second wave
13 formed in the coating step is symmetric about a plane
14 parallel to and intersecting the blood flow axis and
15 bisecting the first leaflet.

16

17 26. The method of claim 21 wherein the second wave
18 formed in the coating step is asymmetric about a
19 plane parallel to and intersecting the blood flow
20 axis and bisecting the first leaflet.

21

22 27. The method of claim 23 wherein the second wave
23 formed in the coating step is symmetric about a plane
24 parallel to and intersecting the blood flow axis and
25 bisecting the first leaflet.

26

27 28. The method of claim 23 wherein the second wave
28 formed in the coating step is asymmetric about a
29 plane parallel to and intersecting the blood flow
30 axis and bisecting the first leaflet.

31

1 29. The method of claim 24 wherein the second wave
2 formed in the coating step is symmetric about a plane
3 parallel to and intersecting the blood flow axis and
4 bisecting the first leaflet.

5

6 30. The method of claim 24 wherein the second wave
7 formed in the coating step is asymmetric about a
8 plane parallel to and intersecting the blood flow
9 axis and bisecting the first leaflet.

10

11 31. The method of claim 21 wherein the first
12 composite wave formed in the coating step is
13 symmetric about a plane parallel to and intersecting
14 the blood flow axis and bisecting the first leaflet.

15

16 32. The method of claim 21 wherein the first
17 composite wave formed in the coating step is
18 asymmetric about a plane parallel to and intersecting
19 the blood flow axis and bisecting the first leaflet.

20

21 33. The method of claim 21 wherein the at least two
22 leaflets formed in the coating step include second
23 and third leaflets and wherein an intersection of the
24 second and third leaflets with the plane
25 perpendicular to the blood flow axis forms second and
26 third composite waves, respectively, the second and
27 third composite waves being substantially the same as
28 the first composite wave.

29

30 34. The method of claim 21 wherein the first wave
31 formed in the coating step is defined by an equation

1 which is one of trigonometric, elliptical,
2 hyperbolic, parabolic, circular, a smooth analytic
3 function and a table of values.

4

5 35. The method of claim 21 wherein the second wave
6 formed in the coating step is defined by an equation
7 which is one of trigonometric, elliptical,
8 hyperbolic, parabolic, circular, a smooth analytic
9 function and a table of values.

10

11 36. The method of claim 31 wherein the first and
12 second waves formed in the coating step are symmetric
13 about a plane parallel to and intersecting the blood
14 flow axis and bisecting the first leaflet.

15

16 37. The method of claim 32 wherein at least one of
17 the first and second waves formed in the coating step
18 is asymmetric about a plane parallel to and
19 intersecting the blood flow axis and bisecting the
20 first leaflet.

21

22 38. The method of claim 21 wherein the at least two
23 leaflets formed in the coating step are configured
24 such that they are substantially free of bending
25 stresses when in the neutral position.

26

27 39. A cardiac valve prosthesis comprising:
28 a frame defining a blood flow axis; and
29 at least two leaflets attached to the frame
30 including a first leaflet having an internal
31 surface facing the blood flow axis and an

1 external surface facing away from the blood flow
2 axis, the first leaflet being configured such
3 that a mean thickness of a first half of the
4 first leaflet is different than a mean thickness
5 of a second half of the first leaflet, the first
6 and second halves being defined by a plane
7 parallel to and intersecting the blood flow axis
8 and bisecting the first leaflet.

9
10 40. The cardiac valve prosthesis of claim 39 wherein
11 the first leaflet is further configured such that a
12 thickness of the first leaflet between the internal
13 and external surfaces along a cross section defined
14 by the intersection of a plane perpendicular to the
15 blood flow axis and the first leaflet increases
16 gradually and substantially continuously from a first
17 end of the cross section to a second end of the cross
18 section.

19
20 41. A method of making a cardiac valve prosthesis
21 which includes a frame defining a blood flow axis
22 substantially parallel to the flow of blood through
23 the valve prosthesis and at least two flexible
24 leaflets attached to the frame, the method
25 comprising:

26 providing a mould having a cavity sized to
27 accommodate the frame;
28 inserting the frame into the mould;
29 inserting the mould into an injection
30 moulding machine;

1 injecting molten polymer into the cavity of
2 the mould to form the at least two leaflets and
3 bond the at least two leaflets to the frame, the
4 cavity being shaped to form the at least two
5 leaflets in a desired configuration, the at
6 least two leaflets being configured to be
7 movable from an open to a closed position, the
8 at least two leaflets having a blood inlet side
9 and a blood outlet side, the at least two
10 leaflets being in the closed position when fluid
11 pressure is applied to the outlet side, being in
12 the open position when fluid pressure is applied
13 to the inlet side and being in a neutral
14 position intermediate the open and closed
15 position in the absence of fluid pressure being
16 applied to the leaflets, the at least two
17 leaflets including a first leaflet having a
18 surface contour such that when the first leaflet
19 is in the neutral position an intersection of
20 the first leaflet with at least one plane
21 perpendicular to the blood flow axis forms a
22 first composite wave, the first composite wave
23 being substantially defined by a first wave
24 combined with at least a second superimposed
25 wave, the first wave having a first frequency,
26 the second wave having a second frequency, the
27 first frequency being different from the second
28 frequency.

29

30 42. The method of claim 41 wherein the first
31 composite wave formed in the injecting step is

1 defined by a first wave combined with second and
2 third waves superimposed over the first wave, the
3 third wave having a third frequency which is
4 different from the first frequency.

5

6 43. The method of claim 41 wherein the first wave
7 formed in the injecting step is symmetric about a
8 plane parallel to and intersecting the blood flow
9 axis and bisecting the first leaflet.

10

11 44. The method of claim 41 wherein the first wave
12 formed in the injecting step is asymmetric about a
13 plane parallel to and intersecting the blood flow
14 axis and bisecting the first leaflet.

15

16 45. The method of claim 41 wherein the second wave
17 formed in the injecting step is symmetric about a
18 plane parallel to and intersecting the blood flow
19 axis and bisecting the first leaflet.

20

21 46. The method of claim 41 wherein the second wave
22 formed in the injecting step is asymmetric about a
23 plane parallel to and intersecting the blood flow
24 axis and bisecting the first leaflet.

25

26 47. The method of claim 43 wherein the second wave
27 formed in the injecting step is symmetric about a
28 plane parallel to and intersecting the blood flow
29 axis and bisecting the first leaflet.

30

1 48. The method of claim 43 wherein the second wave
2 formed in the injecting step is asymmetric about a
3 plane parallel to and intersecting the blood flow
4 axis and bisecting the first leaflet.

5

6 49. The method of claim 44 wherein the second wave
7 formed in the injecting step is symmetric about a
8 plane parallel to and intersecting the blood flow
9 axis and bisecting the first leaflet.

10

11 50. The method of claim 44 wherein the second wave
12 formed in the injecting step is asymmetric about a
13 plane parallel to and intersecting the blood flow
14 axis and bisecting the first leaflet.

15

16 51. The method of claim 41 wherein the first
17 composite wave formed in the injecting step is
18 asymmetric about a plane parallel to and intersecting
19 the blood flow axis and bisecting the first leaflet.

20

21 52. The method of claim 41 wherein the first
22 composite wave formed in the injecting step is
23 asymmetric about a plane parallel to and intersecting
24 the blood flow axis and bisecting the first leaflet.

25

26 53. The method of claim 41 wherein the at least two
27 leaflets formed in the injecting step include second
28 and third leaflets and wherein an intersection of the
29 second and third leaflets with the plane
30 perpendicular to the blood flow axis forms second and
31 third composite waves, respectively, the second and

1 third composite waves being substantially the same as
2 the first composite wave.

3

4 54. The method of claim 41 wherein the first wave
5 formed in the injecting step is defined by an
6 equation which is one of trigonometric, elliptical,
7 hyperbolic, parabolic, circular, a smooth analytic
8 function and a table of values.

9

10 55. The method of claim 41 wherein the second wave
11 formed in the injecting step is defined by an
12 equation which is one of trigonometric, elliptical,
13 hyperbolic, parabolic, circular, a smooth analytic
14 function and a table of values.

15

16 56. The method of claim 51 wherein the first and
17 second waves formed in the injecting step are
18 symmetric about a plane parallel to and intersecting
19 the blood flow axis and bisecting the first leaflet.

20

21 57. The method of claim 52 wherein at least one of
22 the first and second waves formed in the injecting
23 step is asymmetric about a plane parallel to and
24 intersecting the blood flow axis and bisecting the
25 first leaflet.


26

27 58. The method of claim 41 wherein the at least two
28 leaflets formed in the injecting step are configured
29 such that they are substantially free of bending
30 stresses when in the neutral position.


31

- 1 59. A method of designing a cardiac valve prosthesis
2 which includes a frame and at least two flexible
3 leaflets attached to the frame, the method
4 comprising:
5 defining a first desired shape of the
6 leaflets in a first position;
7 defining a second desired shape of the
8 leaflets in a second position different from the
9 first position; and
10 conducting a draping analysis to identify
11 values of adjustable parameters defining at
12 least one of the first and second shapes to
13 ensure that the leaflets are comprised of a
14 sufficient amount and distribution of material
15 for the leaflets to assume both the first and
16 second desired shapes.
17
- 18 60. The method of claim 59 wherein at least one of
19 the first and second positions formed in the defining
20 steps is a closed position and the other of the first
21 and second positions is a partially open position.

1 / 9

*Fig. 1*

2 / 9



3 / 9




Fig. 3




Fig. 4A




Fig. 4B

4 / 9




Fig. 5

5 / 9




Fig. 6




Fig. 7

6 / 9




Fig. 8




Fig. 9

7 / 9




Fig. 10

Fig. 11A




Fig. 11B

8 / 9




Fig. 12




Fig. 13

9 / 9




Fig. 14

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04673

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61F2/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 562 729 A (PURDY DAVID L ET AL) 8 October 1996 (1996-10-08) figure 38 column 11, line 22 - line 47 column 11, line 56 - column 12, line 63 column 13, line 6 - line 45	1, 21, 41, 59, 60
A	---	39
X	US 5 800 527 A (JANSEN ULRICH ET AL) 1 September 1998 (1998-09-01) figures 5-8 column 8, line 50 - column 9, line 31	1
A	---	21, 39, 41, 59
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

28 March 2001

Date of mailing of the international search report

04/04/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mary, C

INTERNATIONAL SEARCH REPORT

Inter. Application No

PCT/GB 00/04673

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 00 62716 A (SULZER CARBOMEDICS INC) 26 October 2000 (2000-10-26) figures 16,21 figures 14,15 page 4, line 31 -page 5, line 9 page 8, line 5 - line 31 page 9, line 2 - line 7	1, 39-41, 59,60
A	----	21
A	US 5 358 518 A (CAMILLI SANTE) 25 October 1994 (1994-10-25) figures 1A,2A,3A,4A column 1, line 50 -column 2, line 61 -----	1,21,39, 41,59

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter national Application No
PCT/GB 00/04673

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5562729	A	08-10-1996	NONE	
US 5800527	A	01-09-1998	DE 4222610 A AT 164058 T CA 2139850 A DE 59308288 D WO 9401060 A EP 0649295 A JP 7509624 T	13-01-1994 15-04-1998 20-01-1994 23-04-1998 20-01-1994 26-04-1995 26-10-1995
WO 0062716	A	26-10-2000	NONE	
US 5358518	A	25-10-1994	IT 1247037 B CA 2056113 A EP 0520126 A	12-12-1994 26-12-1992 30-12-1992